This scrip at Rs 1461 has crossed 20D EMA on daily charts with good volumes for past few days and is poised to cross Rs 1480 on 20W EMA after which it can leap ahead.
Scrip has bottomed out, issues with USFDA resolved, acquisition made earlier bearing fruits from oncoming quarters, debt then reducing, and its sound aggressive management holding substantial stake, it should reward patient share holders adequately now.
Buy with a stoploss of Rs 1440 or so.
Scrip has bottomed out, issues with USFDA resolved, acquisition made earlier bearing fruits from oncoming quarters, debt then reducing, and its sound aggressive management holding substantial stake, it should reward patient share holders adequately now.
Buy with a stoploss of Rs 1440 or so.